ACELRX PHARMACEUT. DL-01 (R5XA) — Cash Flow-to-Debt Ratio
ACELRX PHARMACEUT. DL-01 (R5XA) has a Cash Flow-to-Debt Ratio of -0.19x as of December 2025, meaning its operating cash flow of €-2.44 Million could theoretically repay 0% of its total liabilities (€12.68 Million) in one year. See ACELRX PHARMACEUT. DL-01 leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ACELRX PHARMACEUT. DL-01 Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for ACELRX PHARMACEUT. DL-01 across 5 annual periods. For the full cash flow conversion analysis, see ACELRX PHARMACEUT. DL-01 (R5XA) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for ACELRX PHARMACEUT. DL-01 (2021–2025)
Year-by-year debt coverage analysis for ACELRX PHARMACEUT. DL-01. Check ACELRX PHARMACEUT. DL-01 (R5XA) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.90x | €-11.36 Million | €12.68 Million | ▲ +27.7% |
| 2024 | -1.24x | €-12.68 Million | €10.23 Million | ▲ +55.4% |
| 2023 | -2.78x | €-17.49 Million | €6.29 Million | ▼ -152.0% |
| 2022 | -1.10x | €-28.33 Million | €25.67 Million | ▼ -318.5% |
| 2021 | -0.26x | €-30.00 Million | €113.79 Million | — |